# Infinity Fundamentals

INFI | - USA Stock | ## USD 1.11 0.07 5.93% |

## Infinity Fundamentals | Infinity Select Account or Indicator |

**M**, while Consolidated Income is projected to decrease to (50.2

**M**).

## Infinity Number of Shares Shorted Analysis

Infinity Pharmaceuti's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up. 2019 | 2020 | 2021 | 2022 (projected) | |

Interest Expense | 2.56 M | 2.44 M | 2.2 M | 2.19 M |

Gross Profit | 3.05 M | 1.72 M | 1.55 M | 1.59 M |

Shares Shorted | = | Shorted by Public | + | by Institutions |

## Current Infinity Pharmaceuti Number of Shares Shorted | 2.74 M |

Most of Infinity Pharmaceuti's fundamental indicators, such as Number of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuti is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Compare to competition |

Based on the recorded statements, Infinity Pharmaceuti has 2.74

**M**of outstending shares currently sold short by investors. This is 14.35% lower than that of the Healthcare sector and 46.25% lower than that of the Biotechnology industry. The number of shares shorted for all United States stocks is 41.77% higher than that of the company.## Infinity Pharmaceuti Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Infinity Pharmaceuti's current stock value. Our valuation model uses many indicators to compare Infinity Pharmaceuti value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Infinity Pharmaceuti competition to find correlations between indicators driving Infinity Pharmaceuti's intrinsic value. More Info.Infinity Pharmaceuti is considered the number one company in total debt category among related companies. It is currently regarded as number one stock in earnings per share category among related companies . Infinity Pharmaceuti Total Debt is most likely to decrease significantly in the upcoming years. The last year's value of Total Debt was reported at 1.29 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Infinity Pharmaceuti by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Infinity Pharmaceuti's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Infinity Pharmaceuti's earnings, one of the primary drivers of an investment's value.## Infinity Pharmaceuti Current Valuation Drivers

We derive many important indicators used in calculating different scores of Infinity Pharmaceuti from analyzing Infinity Pharmaceuti's financial statements. These drivers represent accounts that assess Infinity Pharmaceuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Infinity Pharmaceuti's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (1.9 M) | (450.12 K) | (1.88 M) | (1.76 M) | (2.02 M) | (2.07 M) | |

Revenue Per Employee | 272.73 K | 885.84 K | 121.96 K | 74.53 K | 85.72 K | 87.97 K | |

Average Assets | 79.52 M | 56.84 M | 62.83 M | 48.01 M | 43.21 M | 44.34 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (39.83 M) | (10.97 M) | (44.33 M) | (37.56 M) | (43.2 M) | (46.61 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (39.83 M) | (10.97 M) | (44.33 M) | (37.56 M) | (43.2 M) | (46.61 M) | |

Earnings before Tax | (42.55 M) | (11.25 M) | (47.11 M) | (40.49 M) | (46.57 M) | (50.24 M) | |

Average Equity | 58.45 M | 50.8 M | 23.83 M | (12.69 M) | (11.42 M) | (11.72 M) | |

Enterprise Value | 75.36 M | 34.89 M | 34.8 M | 119.15 M | 107.24 M | 110.06 M | |

Free Cash Flow | (36 M) | (4.71 M) | (43.86 M) | (35.78 M) | (41.15 M) | (44.4 M) | |

Invested Capital | 19.15 M | 3.88 M | 18.98 M | 1.11 M | 1 M | 1.03 M | |

Invested Capital Average | 29 M | 10.69 M | 20.72 M | 13.29 M | 11.96 M | 12.27 M | |

Market Capitalization | 102.94 M | 67.1 M | 54.75 M | 136.12 M | 122.51 M | 125.73 M | |

Tangible Asset Value | 59.35 M | 60.22 M | 49.01 M | 39.32 M | 35.39 M | 36.32 M | |

Working Capital | 46.79 M | 52.1 M | 34.88 M | 24.97 M | 22.48 M | 23.07 M |

## Infinity Pharmaceuti Institutional Holders

Institutional Holdings refers to the ownership stake in Infinity Pharmaceuti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Infinity Pharmaceuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Infinity Pharmaceuti's value.Security Type | Shares | Value | ||

Callan Capital Llc | Common Shares | 146.2 K | 329 K | |

Russell Investments Group Ltd | Common Shares | 37.9 K | 85 K | |

Cutler Group Lp | Common Shares | 9.3 K | 20 K | |

National Bank Of Canada | Common Shares | 2.6 K | 6 K | |

Koshinski Asset Management Inc | Common Shares | 2 K | 4.5 K | |

Cutler Group Lp | Put Options | 700 | 1000 | |

Cutler Group Lp | Call Options | 300 | 0.0 | |

Tci Wealth Advisors Inc | Common Shares | 200 | 0.0 | |

Bvf Inc | Common Shares | 8.4 M | 28.7 M |

## Infinity Fundamentals

Return On Equity | (490.76) % | |||

Return On Asset | (38.68) % | |||

Current Valuation | 104.23 M | |||

Shares Outstanding | 89.02 M | |||

Shares Owned by Insiders | 2.17 % | |||

Shares Owned by Institutions | 58.68 % | |||

Number of Shares Shorted | 2.74 M | |||

Price to Earning | (1.63) X | |||

Price to Book | 3.27 X | |||

Price to Sales | 56.99 X | |||

Revenue | 1.84 M | |||

Gross Profit | (26.08 M) | |||

EBITDA | (43.34 M) | |||

Net Income | (44.21 M) | |||

Cash and Equivalents | 90.09 M | |||

Cash per Share | 1.01 X | |||

Total Debt | 1.6 M | |||

Debt to Equity | 0.049 % | |||

Current Ratio | 7.44 X | |||

Book Value Per Share | 0.36 X | |||

Cash Flow from Operations | (39.41 M) | |||

Short Ratio | 1.43 X | |||

Earnings Per Share | (0.56) X | |||

Price to Earnings To Growth | (0.05) X | |||

Number of Employees | 23 | |||

Beta | 1.96 | |||

Market Capitalization | 105.04 M | |||

Total Asset | 288.82 M | |||

Retained Earnings | (783.13 M) | |||

Working Capital | 184.64 M | |||

Current Asset | 254.7 M | |||

Current Liabilities | 70.06 M | |||

Z Score | 36.2 |

## About Infinity Pharmaceuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuti's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuti based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | |

Deferred Revenue | 164.7 K | 169 K |

Revenues | 1.5 M | 1.6 M |

Revenue to Assets | 0.05 | 0.05 |

Revenue Per Employee | 85.7 K | 88 K |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in Infinity Pharmaceuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Transaction History Now

## Transaction HistoryView history of all your transactions and understand their impact on performance |

All Next | Launch Module |

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Infinity Pharmaceuti using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please see Infinity Pharmaceuti Piotroski F Score and Infinity Pharmaceuti Altman Z Score analysis. Note that the Infinity Pharmaceuti information on this page should be used as a complementary analysis to other Infinity Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

## Complementary Tools for Infinity Stock analysis

When running Infinity Pharmaceuti price analysis, check to measure Infinity Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuti is operating at the current time. Most of Infinity Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Infinity Pharmaceuti's price. Additionally, you may evaluate how the addition of Infinity Pharmaceuti to your portfolios can decrease your overall portfolio volatility.

Transaction HistoryView history of all your transactions and understand their impact on performance | Go | |

Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios | Go | |

Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges | Go | |

Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities | Go | |

ETF DirectoryFind actively traded Exchange Traded Funds (ETF) from around the world | Go | |

Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated | Go | |

Technical AnalysisCheck basic technical indicators and analysis based on most latest market data | Go | |

Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. | Go |

The market value of Infinity Pharmaceuti is measured differently than its book value, which is the value of Infinity that is recorded on the company's balance sheet. Investors also form their own opinion of Infinity Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Infinity Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Infinity Pharmaceuti's market value can be influenced by many factors that don't directly affect Infinity Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Infinity Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Infinity Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Infinity Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.